Gamida Cell Stock News

Can these penny stocks make gains moving forward? The post Popular Penny Stocks to Know About as January Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.

Gamida Cell Ltd (GMDA) shares closed today 22.5% higher than it did at the end of yesterday. The stock is currently down 12.6% year-to-date, down 76.4% over the past 12 months, and down 73.7% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.0%. Trading Activity Shares traded as high as $2.42 and as low as $2.14 this week.Shares closed 81.9% below its 52-week high and 29.5% above its 52-week low.Trading volume this week was 25.1% higher than the 10-day average and 54.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 109.5% The company's stock price performance over the past 12 months lags the peer average by 136.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Following a positive Type B meeting with the FDA, Gamida Cell (GMDA) plans rolling BLA submission for omidubicel for blood cancers in need of stem cell transplant.Omidubicel

The stock price of Gamida Cell Ltd (NASDAQ: GMDA) increased by over 20% during intraday trading today. This is why it happened.

Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information |

Planning to initiate rolling BLA submission for omidubicel following positive Type B meeting with FDA Full BLA submission on track for first half of 2022 BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Na

Gamida Cell Ltd (GMDA) shares closed today 12.0% lower than it did at the end of yesterday. The stock is currently down 66.2% year-to-date, down 67.6% over the past 12 months, and down 66.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $3.38 and as low as $2.35 this week.Shares closed 83.3% below its 52-week high and 19.0% above its 52-week low.Trading volume this week was 340.2% higher than the 10-day average and 657.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 119.1% The company's stock price performance over the past 12 months lags the peer average by 116.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Add these penny stocks to your watchlist for 2022 The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for GDA-201, the companys lead candidate in its NAM-enabled NK cell therapy pipeline, will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, being held in Atlanta, Georgia. Additionally, for patients who participated in the phase 3 trial of omidubicel, the company will be pre

Wall Street analysts expect that Gamida Cell Ltd. (NASDAQ:GMDA) will announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Gamida Cell’s earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.43). Gamida Cell […]

Gamida Cell (NASDAQ:GMDA) had its price objective reduced by HC Wainwright from $27.00 to $22.00 in a research report released on Tuesday, The Fly reports. They currently have a buy rating on the stock. Several other brokerages have also issued reports on GMDA. Piper Sandler lowered their price target on Gamida Cell from $23.00 to []

Gamida Cell (NASDAQ:GMDA) had its price objective trimmed by Piper Sandler from $23.00 to $13.00 in a research report released on Tuesday, The Fly reports. The brokerage currently has an overweight rating on the stock. Piper Sandler also issued estimates for Gamida Cells Q4 2021 earnings at ($0.45) EPS, FY2021 earnings at ($1.45) EPS, Q1 []